Skip to main content
Top
Published in: Diagnostic Pathology 1/2017

Open Access 01-12-2017 | Case Report

Case report: ACTH-secreting pituitary carcinoma metastatic to the liver in a patient with a history of atypical pituitary adenoma and Cushing’s disease

Authors: Amy S. Joehlin-Price, Douglas A. Hardesty, Christina A. Arnold, Lawrence S. Kirschner, Daniel M. Prevedello, Norman L. Lehman

Published in: Diagnostic Pathology | Issue 1/2017

Login to get access

Abstract

Background

Pituitary carcinoma is a rare entity requiring the presence of metastasis to confirm its malignant potential. We report a case of pituitary carcinoma and discuss the diagnosis and management of this lesion in relation to the existing literature.

Case presentation

The patient is a 51-year-old woman with Cushing’s disease and intact adrenal glands who was diagnosed with metastatic pituitary carcinoma to the liver, 29 months after initial resection of an ACTH-secreting primary atypical pituitary adenoma (APA). Prior to detection of this metastasis the patient underwent repeat resection and radiotherapy for residual cavernous sinus disease. The metastatic lesion was detected by interval surveillance of serum ACTH and 24-hour urine cortisol, which despite stable pituitary MRI, were significantly elevated. These abnormalities prompted a PET scan that demonstrated hypermetabolic liver parenchyma, which was suspicious for metastasis on abdominal MRI. An ultrasound-guided liver biopsy demonstrated nests of moderately-differentiated cells with intermediate-sized, monotonous nuclei, distinct nucleoli, and abundant basophilic cytoplasm, confirmed by immunohistochemistry to represent metastatic pituitary carcinoma. The liver lesion was subsequently successfully removed by wedge resection. One year later, the patient’s residual cavernous sinus disease grew markedly, and she was placed on dual-agent chemotherapy consisting of oral temozolomide and capecitabine, with stabilization of her intracranial disease to present, although liver metastases recurred.

Conclusions

Pituitary carcinoma is a rare entity impossible to recognize as a primary tumor because its diagnosis by definition requires the presence of metastasis. Maintaining awareness of the entity and its precursor lesion APA is essential for its accurate pathologic diagnosis and appropriate management.
Literature
1.
go back to reference Joehlin-Price AS, Arnold CA, Kirschner LS, Prevedello DM, Lehman NL. ACTH-secreting pituitary carcinoma metastatic to the liver in a patient with a history of atypical pituitary adenoma and Cushing’s syndrome. Neuro Oncol. 2015;15 Suppl 5:v204. Joehlin-Price AS, Arnold CA, Kirschner LS, Prevedello DM, Lehman NL. ACTH-secreting pituitary carcinoma metastatic to the liver in a patient with a history of atypical pituitary adenoma and Cushing’s syndrome. Neuro Oncol. 2015;15 Suppl 5:v204.
3.
go back to reference Pernicone PJ, Scheithauer BW, Sebo TJ, Kovacs KT, Horvath E, Young Jr WF, et al. Pituitary carcinoma: a clinicopathologic study of 15 cases. Cancer. 1997;79:804–12.CrossRefPubMed Pernicone PJ, Scheithauer BW, Sebo TJ, Kovacs KT, Horvath E, Young Jr WF, et al. Pituitary carcinoma: a clinicopathologic study of 15 cases. Cancer. 1997;79:804–12.CrossRefPubMed
4.
go back to reference Saeger W, Ludecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol. 2007;156:203–16.CrossRefPubMed Saeger W, Ludecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol. 2007;156:203–16.CrossRefPubMed
5.
go back to reference Scheithauer BW, Fereidooni F, Horvath E, Kovacs K, Robbins P, Tews D, et al. Pituitary carcinoma: an ultrastructural study of eleven cases. Ultrastruct Pathol. 2001;25:227–42.CrossRefPubMed Scheithauer BW, Fereidooni F, Horvath E, Kovacs K, Robbins P, Tews D, et al. Pituitary carcinoma: an ultrastructural study of eleven cases. Ultrastruct Pathol. 2001;25:227–42.CrossRefPubMed
6.
go back to reference McCutcheon IE, Pieper DR, Fuller GN, Benjamin RS, Friend KE, Gagel RF. Pituitary carcinoma containing gonadotropins: treatment by radical excision and cytotoxic chemotherapy: case report. Neurosurgery. 2000;46:1233–40.CrossRefPubMed McCutcheon IE, Pieper DR, Fuller GN, Benjamin RS, Friend KE, Gagel RF. Pituitary carcinoma containing gonadotropins: treatment by radical excision and cytotoxic chemotherapy: case report. Neurosurgery. 2000;46:1233–40.CrossRefPubMed
7.
go back to reference Kuroki M, Tanaku R, Yokoyama M, Ikura F. Subarachnoid dissemination of a pituitary adenoma. Surg Neurol. 1987;28:71–6.CrossRefPubMed Kuroki M, Tanaku R, Yokoyama M, Ikura F. Subarachnoid dissemination of a pituitary adenoma. Surg Neurol. 1987;28:71–6.CrossRefPubMed
8.
go back to reference Wei Z, Zhou C, Liu M, Yao Y, Sun J, Xiao J, et al. MicroRNA involvement in a metastatic non-functioning pituitary carcinoma. Pituitary. 2015;18:710–21.CrossRefPubMed Wei Z, Zhou C, Liu M, Yao Y, Sun J, Xiao J, et al. MicroRNA involvement in a metastatic non-functioning pituitary carcinoma. Pituitary. 2015;18:710–21.CrossRefPubMed
9.
go back to reference Dudziak K, Honegger J, Bornemann A, Horger M, Mussig K. Pituitary carcinoma with malignant growth from first presentation and fulminant clinical course—case report and review of the literature. J Clin Endocrinol Metab. 2011;96:2665–9.CrossRefPubMed Dudziak K, Honegger J, Bornemann A, Horger M, Mussig K. Pituitary carcinoma with malignant growth from first presentation and fulminant clinical course—case report and review of the literature. J Clin Endocrinol Metab. 2011;96:2665–9.CrossRefPubMed
10.
go back to reference Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Murray D, et al. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery. 1996;38:99–107.CrossRefPubMed Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Murray D, et al. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery. 1996;38:99–107.CrossRefPubMed
11.
go back to reference Gaffey TA, Scheithauer BW, Lloyd RV, Burger PC, Robbins P, Fereidooni F, et al. Corticotroph carcinoma of the pituitary: a clinicopathological study. Report of four cases. J Neurosurg. 2002;96:352–60.CrossRefPubMed Gaffey TA, Scheithauer BW, Lloyd RV, Burger PC, Robbins P, Fereidooni F, et al. Corticotroph carcinoma of the pituitary: a clinicopathological study. Report of four cases. J Neurosurg. 2002;96:352–60.CrossRefPubMed
12.
go back to reference Queiroz LS, Facure NO, Facure JJ, Modesto NP, de Faria JL. Pituitary carcinoma with liver metastases and Cushing syndrome. Arch Pathol. 1975;99:32–5. Queiroz LS, Facure NO, Facure JJ, Modesto NP, de Faria JL. Pituitary carcinoma with liver metastases and Cushing syndrome. Arch Pathol. 1975;99:32–5.
13.
go back to reference Papotti M, Limone P, Riva C, Gatti G, Bussolati G. Malignant evolution of an ACTH-producing pituitary tumor treated with intrasellar implantation of 90-Y. Appl Pathol. 1984;2:10–21.PubMed Papotti M, Limone P, Riva C, Gatti G, Bussolati G. Malignant evolution of an ACTH-producing pituitary tumor treated with intrasellar implantation of 90-Y. Appl Pathol. 1984;2:10–21.PubMed
14.
go back to reference Borba CG, Batista RL, Musolino NRDC, Machado VC, Alcantara AEE, da Silva GO, et al. Progression of an invasive ACTH pituitary macroadenoma with Cushing’s disease to pituitary carcinoma. Case Rep Oncol Med. 2015;2015:810367.PubMedPubMedCentral Borba CG, Batista RL, Musolino NRDC, Machado VC, Alcantara AEE, da Silva GO, et al. Progression of an invasive ACTH pituitary macroadenoma with Cushing’s disease to pituitary carcinoma. Case Rep Oncol Med. 2015;2015:810367.PubMedPubMedCentral
15.
go back to reference Takeuchi K, Hagiwara Y, Kanaya K, Wada K, Shiba M, Kato Y. Drop metastasis of adrenocorticotropic hormone-producing pituitary carcinoma to the cauda equina. Asian Spine J. 2014;8:680–3.CrossRefPubMedPubMedCentral Takeuchi K, Hagiwara Y, Kanaya K, Wada K, Shiba M, Kato Y. Drop metastasis of adrenocorticotropic hormone-producing pituitary carcinoma to the cauda equina. Asian Spine J. 2014;8:680–3.CrossRefPubMedPubMedCentral
16.
go back to reference Shastri BR, Nanda A, Fowler M, Levine SN. Adrenocorticotropic hormone-producing pituitary carcinoma with intracranial metastases. World Neurosurg. 2013;79:404.E11–16.CrossRef Shastri BR, Nanda A, Fowler M, Levine SN. Adrenocorticotropic hormone-producing pituitary carcinoma with intracranial metastases. World Neurosurg. 2013;79:404.E11–16.CrossRef
17.
go back to reference Holthouse DJ, Robbins PD, Kahler R, Knuckey N, Pullan P. Corticotroph pituitary carcinoma: Case report and literature review. Endocr Pathol. 2001;12:329–41.CrossRefPubMed Holthouse DJ, Robbins PD, Kahler R, Knuckey N, Pullan P. Corticotroph pituitary carcinoma: Case report and literature review. Endocr Pathol. 2001;12:329–41.CrossRefPubMed
18.
go back to reference Van der Klaauw AA, Kienitz T, Strasburger CJ, Smit JWA, Romijn JA. Malignant pituitary corticotroph adenomas: report of two cases and a comprehensive review of the literature. Pituitary. 2009;12:57–69.CrossRefPubMed Van der Klaauw AA, Kienitz T, Strasburger CJ, Smit JWA, Romijn JA. Malignant pituitary corticotroph adenomas: report of two cases and a comprehensive review of the literature. Pituitary. 2009;12:57–69.CrossRefPubMed
19.
go back to reference Suzuki K, Morii K, Nakamura J, Kaneko S, Ukisu J, Hanyu O, et al. Adrenocorticotropin-producing carcinoma with metastasis to the liver in a patient with Cushing’s disease. Endocr J. 2002;49:153–8.CrossRefPubMed Suzuki K, Morii K, Nakamura J, Kaneko S, Ukisu J, Hanyu O, et al. Adrenocorticotropin-producing carcinoma with metastasis to the liver in a patient with Cushing’s disease. Endocr J. 2002;49:153–8.CrossRefPubMed
20.
go back to reference Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws Jr ER. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery. 1996;38:765–77.CrossRefPubMed Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws Jr ER. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery. 1996;38:765–77.CrossRefPubMed
21.
go back to reference Lidhar K, Korbonits M, Jordan S, Khalimova Z, Kaltsas G, Lu X, et al. Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors. J Clin Endocrinol Metab. 1999;84:3823–30.CrossRefPubMed Lidhar K, Korbonits M, Jordan S, Khalimova Z, Kaltsas G, Lu X, et al. Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors. J Clin Endocrinol Metab. 1999;84:3823–30.CrossRefPubMed
22.
go back to reference Kulig E, Jin L, Qian X, Horvath E, Kovacs K, Stefaneanu L, et al. Apoptosis in nontumorous and neoplastic human pituitaries: expression of the Bcl-2 family of proteins. Am J Pathol. 1999;154:767–74.CrossRefPubMedPubMedCentral Kulig E, Jin L, Qian X, Horvath E, Kovacs K, Stefaneanu L, et al. Apoptosis in nontumorous and neoplastic human pituitaries: expression of the Bcl-2 family of proteins. Am J Pathol. 1999;154:767–74.CrossRefPubMedPubMedCentral
23.
go back to reference Lloyd RV, Kovacs K, Young Jr WF, et al. Tumors of the pituitary. In: DeLellis RA, Heitz P, Lloyd RV, Eng C, editors. WHO classification of tumors of the endocrine organs: Pathology and genetics of endocrine organs. Lyon: IARC Press; 2004. p. 10–45.22. Lloyd RV, Kovacs K, Young Jr WF, et al. Tumors of the pituitary. In: DeLellis RA, Heitz P, Lloyd RV, Eng C, editors. WHO classification of tumors of the endocrine organs: Pathology and genetics of endocrine organs. Lyon: IARC Press; 2004. p. 10–45.22.
24.
go back to reference Riss D, Jin L, Qian Z, Bayliss J, Scheithauer BW, Young WF, et al. Differential expression of galectin-3 in pituitary tumors. Cancer Res. 2003;63:2251–5.PubMed Riss D, Jin L, Qian Z, Bayliss J, Scheithauer BW, Young WF, et al. Differential expression of galectin-3 in pituitary tumors. Cancer Res. 2003;63:2251–5.PubMed
25.
go back to reference Tziortzioti V, Ruebel KH, Kuroki T, Jin L, Scheithauer BW, Lloyd RV. Analysis of β-catenin mutations and α-, β-, and γ-catenin expression in normal and neoplastic human pituitary tissues. Endocr Pathol. 2001;12:125–36.CrossRefPubMed Tziortzioti V, Ruebel KH, Kuroki T, Jin L, Scheithauer BW, Lloyd RV. Analysis of β-catenin mutations and α-, β-, and γ-catenin expression in normal and neoplastic human pituitary tissues. Endocr Pathol. 2001;12:125–36.CrossRefPubMed
26.
go back to reference Vidal S, Kovacs K, Horvath E, Rotondo F, Kuroki T, Lloyd RV, et al. Topoisomerase IIα expression in pituitary adenomas and carcinomas: relationship to tumor behavior. Mod Pathol. 2002;15:1205–12.CrossRefPubMed Vidal S, Kovacs K, Horvath E, Rotondo F, Kuroki T, Lloyd RV, et al. Topoisomerase IIα expression in pituitary adenomas and carcinomas: relationship to tumor behavior. Mod Pathol. 2002;15:1205–12.CrossRefPubMed
28.
go back to reference Lopes MBS, Scheithauer BW, Schiff D. Pituitary carcinoma: diagnosis and treatment. Endocrine. 2005;28:115–21.CrossRefPubMed Lopes MBS, Scheithauer BW, Schiff D. Pituitary carcinoma: diagnosis and treatment. Endocrine. 2005;28:115–21.CrossRefPubMed
29.
go back to reference Scheithauer BW, Kurtkaya-Yapicier O, Kovacs KT, Young Jr WF, Lloyd RV. Pituitary carcinoma: a clinicopathologic review. Neurosurgery. 2005;56:1066–74. Scheithauer BW, Kurtkaya-Yapicier O, Kovacs KT, Young Jr WF, Lloyd RV. Pituitary carcinoma: a clinicopathologic review. Neurosurgery. 2005;56:1066–74.
30.
go back to reference Park KS, Hwang JH, Hwang SK, Kim S, Park SH. Pituitary carcinoma with fourth ventricle metastasis: treatment by excision and Gamma-knife radiosurgery. Pituitary. 2014;17:514–8.CrossRefPubMed Park KS, Hwang JH, Hwang SK, Kim S, Park SH. Pituitary carcinoma with fourth ventricle metastasis: treatment by excision and Gamma-knife radiosurgery. Pituitary. 2014;17:514–8.CrossRefPubMed
31.
32.
go back to reference Lehman NL, Horoupian DS, Harsh GR. Synchronous subarachnoid drop metastases from a pituitary adenoma with multiple recurrences. J Neurosurg. 2003;98:1120–3.CrossRefPubMed Lehman NL, Horoupian DS, Harsh GR. Synchronous subarachnoid drop metastases from a pituitary adenoma with multiple recurrences. J Neurosurg. 2003;98:1120–3.CrossRefPubMed
33.
go back to reference Hansen TM, Batra S, Lim M, Gallia GL, Burger PC, Salvatori R, et al. Invasive adenoma and pituitary carcinoma: a SEER database analysis. Neurosurgery. 2014;Rev. 37:279–86. Hansen TM, Batra S, Lim M, Gallia GL, Burger PC, Salvatori R, et al. Invasive adenoma and pituitary carcinoma: a SEER database analysis. Neurosurgery. 2014;Rev. 37:279–86.
34.
go back to reference Zemmoura I, Wierinckx A, Vasiljevic A, Jan M, Trouillas J, François P. Aggressive and malignant prolactin pituitary tumors: pathological diagnosis and patient management. Pituitary. 2013;16:515–22.CrossRefPubMed Zemmoura I, Wierinckx A, Vasiljevic A, Jan M, Trouillas J, François P. Aggressive and malignant prolactin pituitary tumors: pathological diagnosis and patient management. Pituitary. 2013;16:515–22.CrossRefPubMed
35.
go back to reference Seltzer J, Carmichael JD, Commins D, Liu CS, Omura E, Chang E, et al. Prolactin-Secreting Pituitary Carcinoma with Dural Metastasis: Diagnosis, Treatment, and Future Directions. World Neurosurg. 2016;91:676.e23–8.CrossRef Seltzer J, Carmichael JD, Commins D, Liu CS, Omura E, Chang E, et al. Prolactin-Secreting Pituitary Carcinoma with Dural Metastasis: Diagnosis, Treatment, and Future Directions. World Neurosurg. 2016;91:676.e23–8.CrossRef
36.
go back to reference Heaney A. Management of aggressive pituitary adenomas and pituitary carcinomas. J Neurooncol. 2014;117:459–68.CrossRefPubMed Heaney A. Management of aggressive pituitary adenomas and pituitary carcinomas. J Neurooncol. 2014;117:459–68.CrossRefPubMed
37.
go back to reference Schweitzer T, Vince GH, Herbold C, Roosen K, Tonn JC. Extraneural metastases of primary brain tumors. J Neurooncol. 2001;53:107–14.CrossRefPubMed Schweitzer T, Vince GH, Herbold C, Roosen K, Tonn JC. Extraneural metastases of primary brain tumors. J Neurooncol. 2001;53:107–14.CrossRefPubMed
38.
go back to reference Syro LV, Ortiz LD, Scheithauer BW, Lloyd R, Lau Q, Gonzalez R, et al. Treatment of pituitary neoplasms with temozolomide: a review. Cancer. 2011;117:454–62.CrossRefPubMed Syro LV, Ortiz LD, Scheithauer BW, Lloyd R, Lau Q, Gonzalez R, et al. Treatment of pituitary neoplasms with temozolomide: a review. Cancer. 2011;117:454–62.CrossRefPubMed
39.
go back to reference Zacharia BE, Gulati AP, Bruce JN, Carminucci AS, Wardlaw SL, Siegelin M, et al. High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): a case series. Neurosurgery. 2014;74:E447–55.CrossRefPubMed Zacharia BE, Gulati AP, Bruce JN, Carminucci AS, Wardlaw SL, Siegelin M, et al. High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): a case series. Neurosurgery. 2014;74:E447–55.CrossRefPubMed
40.
go back to reference Chatzellis E, Alexandraki KI, Androulakis II, Kaltsas G. Aggressive pituitary tumors. Neuroendocrinology. 2015;101:87–104.CrossRefPubMed Chatzellis E, Alexandraki KI, Androulakis II, Kaltsas G. Aggressive pituitary tumors. Neuroendocrinology. 2015;101:87–104.CrossRefPubMed
41.
go back to reference Halevy C, Whitelaw BC. How effective is temozolomide for treating pituitary tumours and when should it be used? Pituitary. 2016. Epub ahead of print. doi:10.1007/s11102-016-0745-y. Halevy C, Whitelaw BC. How effective is temozolomide for treating pituitary tumours and when should it be used? Pituitary. 2016. Epub ahead of print. doi:10.​1007/​s11102-016-0745-y.
42.
go back to reference Murakami M, Mizutani A, Asano S, Katakami H, Ozawa Y, Yamazaki K, et al. A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report. Neurosurgery. 2011;68:E1761–7.CrossRefPubMed Murakami M, Mizutani A, Asano S, Katakami H, Ozawa Y, Yamazaki K, et al. A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report. Neurosurgery. 2011;68:E1761–7.CrossRefPubMed
Metadata
Title
Case report: ACTH-secreting pituitary carcinoma metastatic to the liver in a patient with a history of atypical pituitary adenoma and Cushing’s disease
Authors
Amy S. Joehlin-Price
Douglas A. Hardesty
Christina A. Arnold
Lawrence S. Kirschner
Daniel M. Prevedello
Norman L. Lehman
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2017
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/s13000-017-0624-5

Other articles of this Issue 1/2017

Diagnostic Pathology 1/2017 Go to the issue